CATALYSTYahoo Finance • 15h ago
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?Yahoo Finance report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
Why EBS Stock dropped -5.68% Today — RQD Quant Desk Flash
$6.81 -5.68% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $6.73
Emergent BioSolutions Inc. (EBS) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $349.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on EBS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is EBS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Emergent BioSolutions Inc. (NYSE: EBS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $6.81 (-5.68% 1D, market cap $349.2M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, EBS ranks #290 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does EBS compare to CTNM and SPRY in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EBS carries a Roarable D (48/100 RQD), trailing P/E of 7.0x, gross margin of 56.1%, and ROIC of 8.9%. By comparison, CTNM (Contineum Therapeutics Inc. (Class A)) holds a E grade (28/100 RQD, P/E N/A, ROIC -29.0%, cap $353.3M) and SPRY (ARS Pharmaceuticals Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $336.1M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for EBS?
▼
Per EBS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001367644), Emergent BioSolutions Inc. generated $742.9M in revenue (-28.8% YoY), $52.6M in net income, and $156.8M in free cash flow against $1.32B in total assets and $572.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $6.73 (-1.21%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 21.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-4.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EBS)Realized 20D OHLCV Swing Band: ±11.1%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY EBS SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+13/20 pts (27% of score)
SEC XBRL FY 2025 (10-K): 21.1% FCF Margin ($156.8M FCF) & 56.1% Gross Margin
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+13/20 pts (27% of score)
SEC Form 4 / 13F Thermometer: 65% Net Buy • Cannibal Buyback (-1.52% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$6.91-9% Next Q
56
Q2 (-2Q)Grade C-$6.29+6% Next Q
53
Q3 (-1Q)Grade C-$6.67+2.1% Next Q
51
CurrentGrade D$6.81-5.6% Hist 90D α
48
Trajectory: C (56) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a EBS Turnaround Squeeze
While EBS currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.55) and Max Pain ($7.15) forces dealer call-delta covering toward $14.76.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $EBS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EBS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why EBS Stock dropped -5.68% Today — RQD Quant Desk Flash
Emergent BioSolutions Inc. (EBS) dropped -5.68% to $6.81, trading at 25% of its 52-week range ($4.36 – $14.06). Stretched risk/reward at 7x P/E (9% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 25% of its 52-week range ($4.36 – $14.06) with RSI-14 at 51.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.1% around $6.81 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 56.1% gross margin and $156.8M annual free cash flow.
Live EBS Headlines & Catalysts
MARKET WIREInvesting.com • 18h ago
Why is Emergent Biosolutions stock surging today?Investing.com report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance Singapore • 21h ago
Emergent BioSolutions Inc. (EBS) stock price, news, quote and historyYahoo Finance Singapore report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHGuruFocus • 1d ago
Emergent BioSolutions (EBS) CFO Richard Lindahl to Retire, Shares Drop PremarketGuruFocus report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
Emergent BioSolutions director DeGolyer sells $126k in sharesInvesting.com report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo Finance • 1d ago
Emergent BioSolutions stock falls as CFO plans retirementYahoo Finance report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Under a trading plan, Emergent BioSolutions (EBS) officer Williams sold 3,000 shares at $6.53.Stock Titan report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Emergent BioSolutions stock rises 3.91 percent with USD 368.1 million valuead-hoc-news.de report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHChartMill • 7h ago
Emergent BioSolutions (NYSE:EBS) Shares Fall as Q3 2026 Revenue Misses and Adjusted EBITDA Turns NegativeEmergent BioSolutions Q3 2026 revenue missed estimates by 11.6%; EPS beat, but negative EBITDA and weak margins sent EBS shares down 21% after hours.
MARKET WIREYahoo • 7h ago
Emergent Biosolutions Q3 Earnings Call HighlightsEmergent Biosolutions (NYSE:EBS) reported third-quarter revenue within its guidance range and updated its full-year outlook, while continuing a multiyear transformation focused on cost control, debt reduction, medical co
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EBS)
- ✓Walkthrough of EBS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
EBS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.26%📐 WEDGE COMPRESSION COIL
2026-11-03O $7.22H $7.22L $6.81C $6.81VOL 754.5K
RES: $7.27SUP: $6.23SMA50: $6.55SMA200: $7.97
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
EBS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-8.0%/yr Implied 5Y Growth
vs. -28.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on EBS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for EBS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EBS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EBS)
Health Care Rank #290 of 1016
⚔️ CTNM vs EBS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (EBS vs. CTNM, SPRY, GALT, AVIR)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Emergent BioSolutions Inc. (EBS) ranks #290 by composite RQD confidence (48/100, grade D) and #498 by equity capitalization ($349.2M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently leads its immediate peer cohort in composite quantitative strength at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EBS
ACTIVE
Emergent BioSolutions Inc. | D | 48/100 | 7.0x | 56.1% | 8.9% | -5.68% | $349.2M | Benchmark Subject |
| CTNM Contineum Therapeutics Inc. (Class A) | E | 28/100 | — | — | -29.0% | +0.64% | $353.3M | /ctnm-vs-ebs → |
| SPRY ARS Pharmaceuticals Inc. | E | 20/100 | — | — | -35.0% | -7.65% | $336.1M | /spry-vs-ebs → |
| GALT Galectin Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -5.68% | $335.6M | /galt-vs-ebs → |
| AVIR Atea Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | -4.64% | $329.6M | /avir-vs-ebs → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001367644In its most recent audited fiscal period (FY2025, filed 2025-12-31), Emergent BioSolutions Inc. (EBS) reported GAAP revenue of $742.9M (-28.8% vs. FY2024 revenue of $1.04B , and -29.2% cumulative change since FY2023) , GAAP net income of $52.6M, operating cash flow of $170.6M, and free cash flow of $156.8M (+338.0% YoY). On the balance sheet, EBS closed FY2025 with $1.32B in total assets against $572.1M in total debt (Altman Z-Score: 1.41, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $742.9M | $52.6M | $170.6M | $156.8M | $1.32B | $572.1M |
| FY2024 (FY) | 2024-12-31 | $1.04B | -$190.6M | $58.7M | $35.8M | $1.39B | $663.7M |
| FY2023 (FY) | 2023-12-31 | $1.05B | -$760.5M | -$206.3M | -$206.3M | — | — |
3. EBS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs EBS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Emergent BioSolutions Inc. (NYSE: EBS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $6.81 (-5.68% 1D, market cap $349.2M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, EBS ranks #290 in composite RQD confidence.
How does EBS compare to CTNM and SPRY in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EBS carries a Roarable D (48/100 RQD), trailing P/E of 7.0x, gross margin of 56.1%, and ROIC of 8.9%. By comparison, CTNM (Contineum Therapeutics Inc. (Class A)) holds a E grade (28/100 RQD, P/E N/A, ROIC -29.0%, cap $353.3M) and SPRY (ARS Pharmaceuticals Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $336.1M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for EBS?
Per EBS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001367644), Emergent BioSolutions Inc. generated $742.9M in revenue (-28.8% YoY), $52.6M in net income, and $156.8M in free cash flow against $1.32B in total assets and $572.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is EBS trading relative to its 50-day, 200-day, and 52-week technical levels?
EBS last traded at $6.81 (-5.68% on volume of 754,456 shares), positioning the stock +3.97% above its 50-day simple moving average ($6.55) and -14.55% below its 200-day simple moving average ($7.97). Across its 52-week range of $4.36 to $14.06, EBS sits at the 25.3% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.1% ($6.05 to $7.57).
EBS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is EBS stock moving today?
Why EBS Stock dropped -5.68% Today — RQD Quant Desk Flash. Stretched risk/reward at 7x P/E (9% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 48/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
EBS — Emergent BioSolutions Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:37:35Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, EBS scores 52 out of 100, earning a D+ grade and the verdict "Roarable Sell — Weak Fundamentals / Trim." The fundamental cash engine pillar scores 13 of 20, with ROIC at 8.9% and FCF yield at 0%, indicating limited cash generation relative to the valuation. Whale 13F flow scores 10 of 20, reflecting institutional accumulation and options positioning that the rating characterizes as weak. Insider conviction scores 13 of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 7 of 20, with beta at 1.0 and the rating noting sector sensitivity. Forensic balance sheet scores 9 of 20, with Altman Z at 1.41, Piotroski F at 8 of 9, and Debt/Equity at 1.09.
For a prospective investor, the upside case rests on the low earnings multiple: per the market data, P/E (TTM) is 7 and forward P/E is 6.5, against an EV/EBITDA of 6.6. The downside case rests on weak cash conversion, with the market data showing FCF yield at 0%, and on balance sheet leverage that the forensic pillar flags as a constraint. The rating's verdict frames the risk-adjusted picture as unfavorable at present. This is an educational summary of the rating's components, not personalized advice.
Snapshot
Business
Emergent BioSolutions Inc. is a NYSE-listed issuer classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, the company has a market capitalization of $0.4B. Source data does not describe its specific products, customers, or revenue model.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $742.9M | $100.1M | $52.6M | N/A | $156.8M | $205.4M | $572.1M |
| FY 2024 | $1043.6M | $-108.7M | $-190.6M | N/A | $35.8M | $99.5M | $663.7M |
| FY 2023 | $1049.3M | $-726.4M | $-760.5M | N/A | $-206.3M | N/A | N/A |
Per the SEC financials, revenue declined from $1049.3M in FY 2023 and $1043.6M in FY 2024 to $742.9M in FY 2025, while operating income turned positive at $100.1M in FY 2025 after prior operating losses. Net margin is 7.1% and operating margin is 13.5% per the market data, with gross margin at 56.1%. Per the Roarable RQD rating, ROIC is 8.9%, Altman Z-Score is 1.41, and Piotroski F-Score is 8 of 9. Debt/Equity is 1.09, and FY 2025 debt of $572.1M compares with cash of $205.4M.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts feed, the headlines include a GREEN-flagged catalyst item reporting a 14.4% share gain and asking whether further upside remains. A YELLOW market-wire item reports a surge in the stock. A RED RISK WATCH item reports that the CFO, Richard Lindahl, plans to retire and that shares dropped premarket. A YELLOW item reports a director sale of $126k in shares. A second RED RISK WATCH item reports that the stock fell as the CFO plans retirement. The feed contains no proprietary signals per the Butterfly Supply-Chain Graph, which reports no supply chain.
Open Questions
- What specific products, customers, or contracts generate the reported FY 2025 revenue decline from FY 2024?
- What are the terms and maturities of the $572.1M in FY 2025 debt, and what drives the gap between FY 2025 FCF of $156.8M and the 0% FCF yield in the market data?
- What is the reported EPS for each period, given that the financials list EPS as N/A?
- What is the basis for the planned CFO retirement, and what succession arrangements are disclosed?
- What drove the FY 2023 net loss of $-760.5M, and was it recurring or one-time?
EBS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Emergent BioSolutions Inc. (EBS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 15h ago
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? Yahoo Finance report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 18h ago
Why is Emergent Biosolutions stock surging today? Investing.com report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Singapore • 21h ago
Emergent BioSolutions Inc. (EBS) stock price, news, quote and history Yahoo Finance Singapore report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH GuruFocus • 1d ago
Emergent BioSolutions (EBS) CFO Richard Lindahl to Retire, Shares Drop Premarket GuruFocus report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Emergent BioSolutions director DeGolyer sells $126k in shares Investing.com report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo Finance • 1d ago
Emergent BioSolutions stock falls as CFO plans retirement Yahoo Finance report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Under a trading plan, Emergent BioSolutions (EBS) officer Williams sold 3,000 shares at $6.53. Stock Titan report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Emergent BioSolutions stock rises 3.91 percent with USD 368.1 million value ad-hoc-news.de report covering Emergent BioSolutions Inc. (EBS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
EBS Bull vs. Bear Conversation Board — What's Your Call at $6.81?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EBS 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $7.80 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is EBS (D+ • RQD 52/100) a Buy at $7.22?
Welcome to the EBS (Emergent BioSolutions Inc.) Roar Pit. Current RQD Composite is 52/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $5.56 (-23.0%)
Spot @ $7.22 Pump the brakes on EBS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on EBS, but look at what you are paying: 7.0x trailing P/E with 56.1% gross margins. Unless Emergent BioSolutions Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $8.74 (+21.1%)
Spot @ $7.22 EBS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on EBS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $7.22 (52-wk range $4.36 - $14.06), any beat on forward guidance forces shorts and underweight funds to chase.